NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

Core Viewpoint - NetraMark Holdings Inc. and Pentara Corporation have entered into a partnership to co-brand and launch a novel site intelligence tool aimed at enhancing clinical trial integrity through advanced AI-driven anomaly detection [1][2]. Group 1: Partnership Details - The collaboration will focus on a site intelligence tool that utilizes information-theoretic variability and other metrics to derive a Paradox Risk score for anomaly detection at the participant level [2]. - This tool aims to identify anomalous participants and assess site-level irregularities using only pre-randomization data, addressing potential data integrity issues that could affect study conclusions [2][6]. Group 2: Company Profiles - NetraMark is positioned as a leader in Generative AI and Machine Learning solutions for the pharmaceutical industry, utilizing a novel algorithm to analyze patient data effectively [7]. - Pentara specializes in statistical and data analysis services for the pharmaceutical and biotechnology sectors, focusing on improving drug development outcomes through innovative study design and analysis [9][10]. Group 3: Strategic Implications - The partnership is expected to enable Pentara to proactively mitigate early risks and implement scalable monitoring of clinical trial sites, enhancing confidence in efficacy outcomes [6]. - NetraMark's AI technology will inform sponsors about potential improvements in trial design, extending beyond participant eligibility to earlier stages like pre-trial site selections [5].